The objective of this webinar (45-minute presentation / 15-minute Q&A) is to explore the potential of CHIM, COVID-19 regulatory considerations, working with regulators and how to accelerate your pipeline.
The current SARS-Cov-2 pandemic has brought the world to a standstill. Research groups and drug developers all over the world are scrambling to develop antivirals and vaccines to treat or prevent COVID-19. Longer term, better modeling will be required to test compounds in a controlled clinical setting once the pandemic has abated. Such a model could be a human challenge trial, commonly known as a controlled human infection model, or CHIM.
A coronavirus CHIM could be an ideal tool to support endeavors to develop effective COVID-19 interventions and provide a longer-term platform to support preparations against the emergence of new or novel coronaviruses.
This webinar will highlight the regulatory considerations to implement such a model and speed up the development pathway of much needed drugs and antiviral products.
Target Audience: The webinar is aimed at all vaccine/antiviral drug developers, commercial or academic, and other industry players who may be interested in the subject.
Bruno Speder - SGS Head Clinical Regulatory Affairs & Consultancy
Adrian Wildfire - SGS Scientific Director
Robin Rogiers - SGS Investigator
Cost: No Charge
Can't make a live session? Register now and receive a complimentary recording after the live event.
For further information, please contact: email@example.com_1590645116210